3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Non-Hodgkin
6
Multiple Myeloma
4
Lymphoma, Mantle-Cell
4
Lymphoma
3
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Glioma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Interventions
Standard of Care
3
COH04S1 COVID-19 vaccine
2
remdesivir
1
palbociclib
1
ogalvibart
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
acalabrutinib
1
XAV-19
1
Therapeutics
1
Surveys and Questionnaires
1
Specimen Handling
1
Rabeprazole
1
Prednisone
1
Methylprednisolone
1
IBIO123
1
Glucocorticoids
1
Gelsolin
1
Dexamethasone
1
CVnCoV COVID-19 vaccine
1
COVID-19 Vaccines
1
COVID-19 Serotherapy
1
Atorvastatin
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
palbociclib
×
Lymphoid
×
Clear all
NCT05371275
2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2
Withdrawn